The rare hematologic malignancy known as chronic myelomonocytic leukemia was the subject of a recent study that compared outcomes from patients treated at academic centers versus nonacademic centers.

Chronic myelomonocytic leukaemia (CMML) remains particularly challenging. About half of patients do not respond to hypomethylating agents, the standard available therapy, and most who initially ...

Her medical history was notable for chronic myelomonocytic leukemia, diagnosed 6 years previously and managed expectantly by monitoring the patient's complete blood count. Over several months ...

CML is a slow-growing cancer but may develop into acute leukemia. CML usually affects older adults and is extremely rare in children. Chronic myelomonocytic leukemia (CMML) is a less common type ...

Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML).

London-based Cypriot Michael Kyriacos Efstratiou is appealing to people on the island to find a stem cell donor after he was ...

del(11q), del(5q), del(20q), del(12p), +8 or double including del(5q); proliferative chronic myelomonocytic leukemia (white blood cell count > 13 × 10 9 /L, CMML-MP FAB subtype) with an ...

its novel CCR2-CyTAC™ (Cytotoxicity Targeting Chimera), for the treatment of chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). Results were presented over the weekend in ...

Imetelstat sodium is under clinical development by Geron and currently in Phase I for Juvenile Myelomonocytic Leukemia (JMML).